^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AEE788

    i
    Other names: AEE 788, AEE788, NVP-AEE788, NVP AEE 788
    Company:
    Novartis
    Drug class:
    EGFR inhibitor, HER2 inhibitor, Multi-tyrosine kinase inhibitor
    Related drugs:
    4years
    Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer. (PubMed, Breast Cancer Res Treat)
    mTOR signaling is highly activated in TNBC tumors. As single rapalog treatment is insufficient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    |
    everolimus • Torisel (temsirolimus) • AEE788